Heart Failure Prevention: Mission Impossible?

Slides:

Advertisements

Similar presentations

Effect of Rapid Clinic Follow-Up After Hospital Discharge on 30- Day Heart Failure Readmission Lee Arcement, MD, MPH Dragana Lovre, MD.

Advertisements

Part I: STEMI BootCamp The 5 “R’s” of Reperfusion”

The Mount Sinai Health System Experience. What is PACT? The Preventable Admissions Care Team is… An intensive, short-term transitional care program.

Each Home Instead Senior Care franchise office is independently owned and operated. Each Home Instead Senior Care ® franchise office is independently owned.

RHP 14 Learning Collaborative July 18, DSRIP Project Overview  Key project areas at Odessa Regional Medical Center Speech Pathology Diabetes Education.

The Integrated Croydon Cardiac Rehabilitation Team Nurses - Sarah Hicks, Mary Stanley, Angela White, Elisabeth Visagie and Carmel Messenger Physiotherapist.

December Cardiac Rehabilitation Are you or someone you know missing the benefits of Cardiac Rehabilitation?

ACOVE 4: Continuity and Coordination of Care in Vulnerable Elders Continuity is ‘‘care over time by a single individual or team of healthcare professionals’’

Heart Failure Devices: Staying Connected Lisa D. Rathman, MSN, CRNP, CCRN, CHFN The Heart Group of Lancaster General Health Lancaster, PA.

Acute Coronary Syndromes in West Hertfordshire Masood Khan.

Transitions in Care-Heart Failure

PRISM-PLUS: Demographics of Patients With Diabetes

Proposed Cataract Pathway

CLINICAL DILEMMAS IN HEART FAILURE:

Preventing Thrombotic Complications in ACS: State of the Art

Welcome! Mission: Lifeline STEMI Task Force Meeting May 17th, 2016

Brief History on Mission: Lifeline

Cardiac Troponin.

Heart Failure and Hospital Readmissions

A CASE CHALLENGE IN HFrEF:

Diagnostic Algorithms for ACS and High-Sensitivity Troponin

Cardiac Biomarkers.

Patient Presentation Patient’s Changing Condition Multiple Considerations To Balance.

Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

It’s Elementary.

Global Burden of VTE. Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care.

Adverse Neurohormonal Activation in HF Has Formed the Basis for Evidence-Based Pharmacologic Therapy

STEMI-INITIAL PRESENTATION TIMING 2013 ACC/AHA GUIDELINES

Heart Failure Management Coordinated Care Approaches

Treating Vasodilatory Shock in the ICU

Treating HFrEF: Challenges Faced

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Treatment Options to Consider

Program Overview. Treatment Options for Post-MI patients with LVD – are all ACE Inhibitors Equal?

OptiLink HF Trial design: Patients with heart failure who underwent implantation of an ICD were randomized to telemonitoring (n = 505) vs. usual care (n.

Selected Causes of Cardiac Injury PEACE Trial High-Sensitivity Biomarker Substudy.

Preventing Heart Failure Readmission and Progression

Managing Depression is a Team Effort:

VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =

The Heart Failure Team Heart Failure Care Map First 24 hours.

Remote Patient Management:

Evaluating New Therapies in HF

The Importance of Getting the Dose Right in HF

Taking the "Cryptogenic" Out of Cryptogenic Stroke

Learning Objectives CMS Measures in HF: 30-day Hospital Readmission Rates.

Updates in Heart Failure:

Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Challenging the Myths in Heart Failure With Reduced Ejection Fraction

Case 1 Presentation Case 1 (cont) Assessment and Recommendations.

Principal recommendations

CAD and HF Often Coexist

New Strategies to Reduce HF Readmissions

Managing HF in Primary Care

[Hospital/Facility Name/Logo]

Improving Adherence to Antiplatelet Therapy After an ACS Event

Assessing the Burden of Hyperkalemia

Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

Taking the "Cryptogenic" Out of Cryptogenic Stroke

Assessing the Burden of Hyperkalemia

In-Hospital Treatment for Heart Failure: New Approaches and a Renewed Sense of Hope?

ESC Guideline on the Management of STEMI Recommendation for DAPT

Recurrence of HF hospitalization Total-time approach

Cohort and Community Surveillance Components

Top Tips in Evidence-Based Care for HFrEF

Key Data on Improving Outcomes in HF Patients

QUALITY: COORDINATED CARE

Case Study #1. Management of Heart Failure With Comorbidities: Challenging Cases for the Cardiologist.

Many post-MI patients are not receiving optimal therapy

What Do the Guidelines Say About The Role of the HF Nurse?

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

Heart Failure Prevention: Mission Impossible?

Case Study

Case Study (cont)

Pre-Hospital ECG

So What Are Our Goals for This Patient?

Case Study - The Next Day

Case Study - 72 Hours Later

HOPE Study: ACE-I Usage and No HF

Benefit of ACE-I: HF Reduction

Patient Management Post PCI

Benefit of MRAs in HF

Case Study - Prior to Hospital Discharge

Questions Prior to Hospital Discharge

Benefits of Cardiac Rehab - Post MI

Labs - Prior to Hospital Discharge

Managing Up-Titration of Medications

Case Study: Visit Week 2 - Post Discharge

ESC STEMI Guideline Recommendations: MRAs??

Follow-Up Assessment of EF and ICD Consideration: When??

Patient Goals of Care: How Did We Do?

Final Thoughts - End of the First Outpatient Visit

Abbreviations

Abbreviations (cont)